The Geographic Atrophy Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

DelveInsight’s Geographic Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, Geographic Atrophy emerging drugs, Geographic Atrophy market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key takeaways from the Geographic Atrophy Market Report

• In the 7MM, the total Geographic Atrophy diagnosed cases were 2,742,600+ cases in 2020.
• In the 7MM, the total Geographic Atrophy treated cases were 1,267,300+ cases in 2020.
• In the year 2020, the total Geographic Atrophy prevalent case was 2,969,900+ cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
• Leading Geographic Atrophy companies such as Apellis Pharmaceuticals, Iveric Bio, Hemera Biosciences, Gyroscope Therapeutics, Stealth BioTherapeutics, Roche (Genentech), CellCure Neurosciences, and many others.
• The promising Geographic Atrophy therapies in the pipeline such as Zimura (Avacincaptad Pegol), Pegcetacoplan, HMR59/AAVCAGsCD59, Risuteganib, Elamipretide, ALK-001, Palucorcel/CNTO 2476, and many others

 

Know which therapies are expected to grab major Geographic Atrophy Market Share @ Geographic Atrophy Market Research Report

Geographic Atrophy Overview

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.

Currently, there are no approved treatments present for Geographic Atrophy. The Age-Related Eye Disease Study (AREDS) study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene, and zinc could significantly reduce the risk of progressing to advanced AMD, and sometimes low visual aids and counseling is also helpful. Several therapies which reached an advanced stage of development are already failed, however, currently, several therapies are in the pipeline to prevent the progression of GA.

Geographic Atrophy Epidemiology Insights

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Geographic Atrophy Epidemiology Segmentation –

Total Geographic Atrophy Prevalent Cases

Total Geographic Atrophy Diagnosed cases

Treated cases of Geographic Atrophy

Diagnosed cases of Geographic Atrophy by Age Distribution

Total Geographic Atrophy Cases by Visual Impairment

 

For further information of this report to understand which factors are driving Geographic Atrophy epidemiology trends @ Geographic Atrophy Epidemiological Insights

Geographic Atrophy Market

As per DelveInsight, the Geographic Atrophy Market is expected to grow significantly in the upcoming years owing to the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies, increasing prevalent patient pool, and a better understanding of pathophysiology, disease severity which might open the door for other companies as well.

Geographic Atrophy Market Dynamics

The Geographic Atrophy (GA) market dynamics is anticipated to change in the coming years owing to the launch of novel drugs and rising healthcare spending across the world.

Geographic Atrophy Pipeline Companies and Therapies

• Apellis Pharmaceuticals: Zimura (Avacincaptad Pegol)
• Iveric Bio: Pegcetacoplan
• Hemera Biosciences: HMR59/AAVCAGsCD59
• Gyroscope Therapeutics: Risuteganib
• Stealth BioTherapeutics: Elamipretide
• Roche (Genentech): ALK-001
• CellCure Neurosciences: Palucorcel/CNTO 2476

Scope of the Geographic Atrophy Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period-2022-2032
• Geographic Atrophy companies- Apellis Pharmaceuticals, Iveric Bio, Hemera Biosciences, Gyroscope Therapeutics, Stealth BioTherapeutics, Roche (Genentech), CellCure Neurosciences, and many others.
• Geographic Atrophy therapies- Zimura (Avacincaptad Pegol), Pegcetacoplan, HMR59/AAVCAGsCD59, Risuteganib, Elamipretide, ALK-001, Palucorcel/CNTO 2476, and many others
• Geographic Atrophy Therapeutic Assessment- Current marketed and emerging therapies
• Geographic Atrophy Market Dynamics- Geographic Atrophy Market Drivers and Barriers
• Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Geographic Atrophy Market Access and Reimbursement

Table of Content

1. Key Insights

2. Executive Summary of Geographic Atrophy (GA)

3. Competitive Intelligence Analysis for Geographic Atrophy (GA)

4. Geographic Atrophy (GA): Market Overview at a Glance

5. Geographic Atrophy (GA): Disease Background and Overview

6. Patient Journey

7. Geographic Atrophy (GA) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy (GA) Unmet Needs

10. Key Endpoints of Geographic Atrophy (GA) Treatment

11. Geographic Atrophy (GA) Marketed Products

12. Geographic Atrophy (GA) Emerging Therapies

13. Geographic Atrophy (GA): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Geographic Atrophy Market Outlook

16. Access and Reimbursement Overview of Geographic Atrophy (GA)

17. KOL Views

18. Geographic Atrophy Market Drivers

19. Geographic Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Discover more about Geographic Atrophy Medications in development @ Geographic Atrophy Clinical Trials

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/